Bloomberg Talks
Moderna CEO Stephane Bancel Talks Fourth Quarter Results
Feb 22, 2024
Moderna CEO discusses market share growth, mRNA vaccines, and plans for new RSV vaccine in 2023. Also explores advancements in RSV, flu, and cancer vaccines, potential of single-shot COVID, flu, and RSV combo vaccine, and competition concerns.
05:20
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Moderna increased market share by differentiating mRNA vaccine and partnering with pharmacies, growing from 30% to 48%
- Moderna focuses on innovation beyond COVID, developing vaccines for RSV and potential COVID/flu combo vaccine in single dose
Deep dives
Moderna's Success in COVID Vaccine Market Share
Moderna's CEO, Stefan Bansell, discussed the company's success in increasing its market share for COVID vaccines. By differentiating their mRNA vaccine from others and partnering with pharmacies, Moderna was able to secure a higher market share, growing from 30% to 48%. Bansell emphasized Moderna's focus on more than just COVID vaccines, highlighting their developments in areas like melanoma and cancer prevention.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
